Color Trails Test: A New Set of Data on Cognitive Flexibility and Processing Speed in Schizophrenia.
cognitive flexibility
cognitive functions
executive functions
processing speed
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
01
2019
accepted:
21
05
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
Although schizophrenia patients have been reported to manifest deficits in cognitive flexibility and lower processing speed (measured with i.a., the Color Trails Test, CTT), there still remain a few matters that require further investigation. We have therefore formulated three research aims: 1) to examine the factor structure of CTT in schizophrenia patients and healthy controls, 2) to compare different CTT performance measures in the two groups, 3) to investigate the relationship between these measures and selected psychopathological symptoms in the patient group. Sixty-seven patients with paranoid schizophrenia and 67 healthy controls, matched for gender, age, number of years of education, and overall cognitive functioning underwent assessment of cognitive flexibility and processing speed with the CTT. Factor analysis of CTT variables based on the principal component method revealed a four-factor solution in both groups. Compared with healthy controls, the patients performed poorer on CTT 1 time, CTT 2 time, 2-1 difference, prompts in CTT 2, and had higher regression factor scores for Factor 1 (reflecting the slower speed of perceptual tracking). Furthermore, significant links were found between some CTT measures, and negative and disorganization symptoms. Schizophrenia patients exhibit problems with speed of perceptual tracking and executive processes dependent on processing speed. Our results may be useful for the development of neuropsychological diagnostic methods for schizophrenia patients. It seems that, compared to other CTT indices, CTT 1 time, CTT 2 time, and 2-1 difference are more appropriate measures of cognitive performance in schizophrenia patients.
Sections du résumé
BACKGROUND
BACKGROUND
Although schizophrenia patients have been reported to manifest deficits in cognitive flexibility and lower processing speed (measured with i.a., the Color Trails Test, CTT), there still remain a few matters that require further investigation. We have therefore formulated three research aims: 1) to examine the factor structure of CTT in schizophrenia patients and healthy controls, 2) to compare different CTT performance measures in the two groups, 3) to investigate the relationship between these measures and selected psychopathological symptoms in the patient group.
METHODS
METHODS
Sixty-seven patients with paranoid schizophrenia and 67 healthy controls, matched for gender, age, number of years of education, and overall cognitive functioning underwent assessment of cognitive flexibility and processing speed with the CTT.
RESULTS
RESULTS
Factor analysis of CTT variables based on the principal component method revealed a four-factor solution in both groups. Compared with healthy controls, the patients performed poorer on CTT 1 time, CTT 2 time, 2-1 difference, prompts in CTT 2, and had higher regression factor scores for Factor 1 (reflecting the slower speed of perceptual tracking). Furthermore, significant links were found between some CTT measures, and negative and disorganization symptoms.
CONCLUSIONS
CONCLUSIONS
Schizophrenia patients exhibit problems with speed of perceptual tracking and executive processes dependent on processing speed. Our results may be useful for the development of neuropsychological diagnostic methods for schizophrenia patients. It seems that, compared to other CTT indices, CTT 1 time, CTT 2 time, and 2-1 difference are more appropriate measures of cognitive performance in schizophrenia patients.
Identifiants
pubmed: 32581889
doi: 10.3389/fpsyt.2020.00521
pmc: PMC7296107
doi:
Types de publication
Journal Article
Langues
eng
Pagination
521Informations de copyright
Copyright © 2020 Tyburski, Karabanowicz, Mak, Lebiecka, Samochowiec, Pełka-Wysiecka, Sagan and Samochowiec.
Références
Arch Gen Psychiatry. 2007 May;64(5):532-42
pubmed: 17485605
Neurosci Bull. 2015 Apr;31(2):207-19
pubmed: 25761914
Arch Clin Neuropsychol. 2007 May;22(4):433-47
pubmed: 17336493
Psychol Med. 2009 Mar;39(3):381-92
pubmed: 18588741
BMC Psychiatry. 2012 Jun 20;12:64
pubmed: 22715980
Psychiatry Res. 2008 Jan 15;157(1-3):67-76
pubmed: 17928068
Psychiatry Investig. 2018 Oct;15(10):945-955
pubmed: 30223641
Schizophr Res. 2006 Jul;85(1-3):20-9
pubmed: 16616831
Clin Neuropsychol. 2006 Jun;20(2):271-88
pubmed: 16690547
Ind Psychiatry J. 2011 Jul;20(2):107-14
pubmed: 23271865
Am J Psychiatry. 2010 Jul;167(7):828-35
pubmed: 20439390
J Psychiatr Res. 2004 Mar-Apr;38(2):145-52
pubmed: 14757328
Schizophr Res. 2005 Jan 1;72(2-3):185-93
pubmed: 15560963
Schizophr Res. 2013 Jul;147(2-3):339-47
pubmed: 23706416
Schizophr Res. 2012 Mar;135(1-3):34-9
pubmed: 22222379
Eur Arch Psychiatry Clin Neurosci. 2006 Sep;256(6):364-71
pubmed: 16788772
Intelligence. 2011 Jul;39(4):222-232
pubmed: 21789028
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Psychiatry Res. 2015 Dec 15;230(2):172-80
pubmed: 26350702
J Clin Exp Neuropsychol. 1998 Apr;20(2):280-5
pubmed: 9777482
Arch Clin Neuropsychol. 1989;4(4):393-8
pubmed: 14591136
Semin Clin Neuropsychiatry. 1999 Jan;4(1):5-12
pubmed: 10229788
Psychol Rev. 1996 Jul;103(3):403-28
pubmed: 8759042
Biol Psychiatry. 2008 Nov 1;64(9):823-7
pubmed: 18472089
Schizophr Res. 2003 May 1;61(1):47-57
pubmed: 12648735
J Am Geriatr Soc. 1992 Sep;40(9):922-35
pubmed: 1512391
Arch Clin Neuropsychol. 2008 Mar;23(2):129-37
pubmed: 18178372
Psychiatry Res. 2008 Mar 15;158(2):195-205
pubmed: 18243336
Arch Clin Neuropsychol. 2000 Jul;15(5):425-31
pubmed: 14590218
Front Psychiatry. 2013 Jun 24;4:35
pubmed: 23805107
PLoS One. 2017 Feb 28;12(2):e0172114
pubmed: 28245266
PLoS One. 2014 Nov 03;9(11):e111562
pubmed: 25365028
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683